Thalidomide in patients with advanced multiple myeloma: A study of 83 patients - Report of the intergroupe francophone du myélome (IFM)

Hematology Journal

Volumn 3, Issue 4, 2002, Pages 185-192

  Yakoub Agha, Ibrahim ^a   Attal, Michel ^a   Dumontet, Charles ^a   Delannoy, Válerie ^a   Moreau, Philippe ^a   Berthou, Christian ^a   Lamy, Thierney ^a   Grosbois, Bernard ^a   Dauriac, Charly ^a   Dorvaux, Véronique ^a   Bay, Jacques Olivier ^a   Monconduit, Matthieu ^a   Harousseau, Jean Luc ^a   Duguet, Corinne ^a   Duhamel, Alain ^a   Facon, Thierry ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Multiple myeloma; Prognostic factors; Thalidomide

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; MORPHINE DERIVATIVE; THALIDOMIDE;

ADULT; ADVANCED CANCER; AFFECTIVE NEUROSIS; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOTRANSPLANTATION; BONE PAIN; CANCER GROWTH; CANCER SURVIVAL; CHRONOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; EDEMA; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; PROGNOSIS; RISK ASSESSMENT; SOMNOLENCE; THROMBOCYTE COUNT; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG EVALUATION; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN A; LIFE TABLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; SALVAGE THERAPY; SERUM ALBUMIN; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036380265     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200175     Document Type: Article

References (27)

1. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-342.
2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484-489.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A propsective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francias du Myelome. N Engl J Med 1996; 335: 91-97.
4. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
5. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
6. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-978.
7. Ribatti D, Vacca A, Nico B, Quondamatteao F, Ria R, Minishcetti M et al. Bone marow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79: 451-455.
8. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
9. Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadaleta-Caldarola G, Iodice G et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995; 50: 9-14.
10. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
11. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81: 219-223.
12. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
13. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996; 2: 506-515.
14. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med 1998; 187: 1885-1892.
15. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213-221.
16. Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumontet C et al. Thalidomide in patients with advanced multiple myeloma. The Hematology Journal 2000; 1: 186-189.
17. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in ptients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96.
18. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
19. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat SOC 1972; 135.
21. Cox D. Regression models and life tables (with discussion). J R Stat SOC 1972; 34: 187-220.
22. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M et al. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol 2000; 108: 391-393.
23. Durie BG, Stepan DE. Low dose thalidomide: alone and in combination. VIIIth International Myeloma Workshop, 2001, Banff, Canada: May 4-8.
24. Chen CI, Adesanya A, Sutton DM, Brandwein J, Stewart AK. Low-dose thalidomide in patients with advanced, refractory multiple myeloma. Blood 1999; 94: 4608a.
25. Weber DM, Gavinoino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 1999; 94: 2686a.
26. Coleman M, Gelfand RM, Leonard JP. Combination non-myelosuppressive therapy (thalidomide, claritromycine, dexamethasone) for plasma cell myeloma: a preliminary report. Blood 1999; 94: 4604a.
27. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.